Interim report January – September 2013
High growth and improved income
Third quarter:
Continuing operations
- Sales growth was 33 percent in local currency. Sales amounted to SEK 109 (83) million, corresponding to an increase of 31 percent in SEK.
- Operating income (EBIT) amounted to SEK 23 (15) million, corresponding to an operating margin of 21 (18) percent.
- The comparative figures for 2012 relate to continuing operations, fertility, unless otherwise stated.
- Net income amounted to SEK 17 (9) million, which gave earnings per share of SEK 0.85 (0.45).
- Agreement with Xvivo Perfusion AB to terminate contract manufacturing of STEEN Solution™ during the fourth quarter of 2013.
January - September:
Continuing operations
- Sales growth was 30 percent in local currency. Sales amounted to SEK 329 (264) million, corresponding to an increase of 25 percent in SEK.
- Operating income (EBIT) amounted to SEK 59 (38) million, corresponding to an operating margin of 18 (14) percent.
- The comparative figures for 2012 relate to continuing operations, fertility, unless otherwise stated.
- Net income amounted to SEK 41 (27) million, which gave earnings per share of SEK 2.06 (1.36).
Gothenburg, November 7, 2013
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 7, 2013 at 08:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
_________________________________________________________________________________________________________________
Vitrolife is an international medical device Group. Vitrolife Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife has approximately 230 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
_________________________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/
